デフォルト表紙
市場調査レポート
商品コード
1098619

脊髄性筋萎縮症の市場規模・シェア・展望・機会 (2022年~2030年):タイプ・治療法・年齢層・投与経路・流通経路・地域別

Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 156 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
脊髄性筋萎縮症の市場規模・シェア・展望・機会 (2022年~2030年):タイプ・治療法・年齢層・投与経路・流通経路・地域別
出版日: 2022年06月09日
発行: Coherent Market Insights
ページ情報: 英文 156 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

主要企業による製品上市の増加が予測期間中の脊髄性筋萎縮症市場の成長を促進すると予想されています。また、主要企業による提携・協力などの無機的戦略の採用の増加も予測期間中の市場成長の原動力になると予想されています。

当レポートでは、世界の脊髄性筋萎縮症の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、技術動向、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・規制・動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 買収・提携
  • 技術の進歩
  • 規制シナリオ
  • PEST分析
  • 製品発売

第4章 世界の脊髄性筋萎縮症市場:COVID-19の影響

  • 全体的な影響
  • 政府のイニシアチブ
  • COVID-19:市場への影響

第5章 世界の脊髄性筋萎縮症市場:タイプ別

  • 概要
  • タイプI
  • タイプII
  • タイプIII
  • タイプIV

第6章 世界の脊髄性筋萎縮症市場:治療別

  • 概要
  • 遺伝子治療
  • 疾患修飾薬

第7章 世界の脊髄性筋萎縮症市場:年齢別

  • 概要
  • 小児
  • 成人

第8章 世界の脊髄性筋萎縮症市場:投与経路別

  • 概要
  • 経口
  • 注射

第9章 世界の脊髄性筋萎縮症市場:流通経路別

  • 概要
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 世界の脊髄性筋萎縮症市場:地域別

  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第11章 競合情勢

  • Biogen
  • CYTOKINETICS
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • PTC Therapeutics, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals
  • Chugai Pharmaceutical Co., Ltd.
  • NMD PHARMA A/S
  • Astellas Pharma Inc.

第12章 セクション

目次
Product Code: CMI1920

Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.

Market Dynamics

The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).

Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2021, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.

Key features of the study:

  • This report provides in-depth analysis of the global spinal muscular atrophy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market

Detailed Segmentation:

  • Global Spinal Muscular Atrophy Market, By Type:
  • Type I
  • Type II
  • Type III
  • Type IV
  • Global Spinal Muscular Atrophy Market, By Treatment:
  • Gene Therapy
  • Disease-modifying drugs
  • Global Spinal Muscular Atrophy Market, By Age Group:
  • Infant
  • Adult
  • Global Spinal Muscular Atrophy Market, By Route of Administration:
  • Oral
  • Injectables
  • Global Spinal Muscular Atrophy Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Spinal Muscular Atrophy Market, By Region:
  • North America
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • U.S.
    • Canada
  • Latin America
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
  • Biogen
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • CYTOKINETICS
  • Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • PTC Therapeutics, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals
  • Chugai Pharmaceutical Co., Ltd.
  • NMD PHARMA A/S
  • Astellas Pharma Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type
    • Market Snapshot, By Treatment
    • Market Snapshot, By Age
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Acquisitions and Partnerships Scenario
  • Technological Advancements
  • Regulatory Scenario
  • PEST Analysis
  • Product Launches

4. Global Spinal Muscular Atrophy Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Spinal Muscular Atrophy Market, By Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Type I
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type II
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type III
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type IV
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Spinal Muscular Atrophy Market, By Treatment, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Gene Therapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Disease-modifying drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Spinal Muscular Atrophy Market, By Age, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Infant
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Spinal Muscular Atrophy Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Injectables
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

10. Global Spinal Muscular Atrophy Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

11. Competitive Landscape

  • Biogen
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CYTOKINETICS
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Genentech, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • PTC Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ionis Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Chugai Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • NMD PHARMA A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

12. Section

  • Research Methodology
  • About Us